Cargando…
(11)C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to α‐Synuclein Fibrils in vitro and Crosses the Blood‐Brain Barrier
There is an urgent clinical need for imaging of α‐synuclein (αSyn) fibrils, the hallmark biomarker for Parkinson's disease, in neurodegenerative disorders. Despite immense efforts, promising tracer candidates for nuclear imaging of αSyn are rare. Diphenyl pyrazoles are known modulators of αSyn...
Autores principales: | Maurer, Andreas, Leonov, Andrei, Ryazanov, Sergey, Herfert, Kristina, Kuebler, Laura, Buss, Sabrina, Schmidt, Felix, Weckbecker, Daniel, Linder, Ruth, Bender, Dirk, Giese, Armin, Pichler, Bernd J., Griesinger, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079211/ https://www.ncbi.nlm.nih.gov/pubmed/31859430 http://dx.doi.org/10.1002/cmdc.201900689 |
Ejemplares similares
-
[(11)C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates
por: Kuebler, Laura, et al.
Publicado: (2020) -
Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
por: Heras‐Garvin, Antonio, et al.
Publicado: (2018) -
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
por: Antonschmidt, Leif, et al.
Publicado: (2022) -
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
por: Lemos, Miguel, et al.
Publicado: (2020) -
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
por: Levin, Johannes, et al.
Publicado: (2014)